Overview

Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia

Status:
Enrolling by invitation

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo-Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa-Induced Dyskinesia in Subjects with Parkinson's Disease.

Phase:

Phase 2

Details

Lead Sponsor:

PharmaTher Inc.

Treatments:

Ketamine
Midazolam